Literature DB >> 7665644

Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases.

M Yamamoto1, H Kimura, T Hironaka, K Hirai, S Hasegawa, K Kuzushima, M Shibata, T Morishima.   

Abstract

Epstein-Barr virus (EBV) causes various diseases, such as infectious mononucleosis (IM), fatal IM, EBV-associated hemophagocytic syndrome (EBVAHS), and chronic active EBV infection (CAEBV). In the present study, cell-free EBV DNA was detected in the plasma of patients with EBV-associated diseases by PCR assay. The patients included 20 patients with IM, 2 patients with fatal IM, 4 patients with EBVAHS, 4 patients with CAEBV, and 38 healthy children (20 EBV seropositive and 18 EBV seronegative). In patients with IM, plasma samples were positive for EBV DNA in all patients (100%) in the acute phase and in 44% of the patients in the convalescent phase, but plasma samples from the 38 healthy control children were negative (0%) for EBV DNA. Quantitative PCR assay revealed that plasma from patients with IM contained the highest amount of virus DNA within 7 days following the onset of disease (mean, 6 x 10(4) copies per ml). The EBV DNA concentration decreased thereafter as the patients recovered. Plasma from patients with fatal IM contained more than 100 times more copies of EBV DNA (3 x 10(7) copies per ml) than plasma from patients with IM. Plasma from patients with the acute phase of EBVAHS contained 10 times more copies of EBV DNA (5 x 10(5) copies per ml) than plasma from IM, and then patients with the number of copies decreased similarly in both groups of patients in the convalescent phase (2 x 10(4) copies per ml). The amount of virus DNA in patients with CAEBV (6 x 10(4) copies per ml) was similar to that noted in patients with IM; however, it became higher (1 x 10(6) copies per ml) when the patients' clinical status deteriorated. These data suggest that the presence of cell-free EBV DNA in plasma is a common phenomenon in patients with EBV-associated diseases. The concentration of EBV DNA in plasma seems to be higher in patients with the more severe clinical categories of EBV diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665644      PMCID: PMC228265          DOI: 10.1128/jcm.33.7.1765-1768.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

Review 1.  Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients.

Authors:  D T Purtilo; E Tatsumi; G Manolov; Y Manolova; S Harada; H Lipscomb; G Krueger
Journal:  Int Rev Exp Pathol       Date:  1985

2.  Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome.

Authors:  E C Mroczek; D D Weisenburger; H L Grierson; R Markin; D T Purtilo
Journal:  Arch Pathol Lab Med       Date:  1987-06       Impact factor: 5.534

3.  Cloning and mapping of BamHi endonuclease fragments of DNA from the transforming B95-8 strain of Epstein-Barr virus.

Authors:  J Skare; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

4.  Clustered repeat sequences in the genome of Epstein Barr virus.

Authors:  M D Jones; B E Griffin
Journal:  Nucleic Acids Res       Date:  1983-06-25       Impact factor: 16.971

5.  Epstein-Barr virus infectious mononucleosis in children. I. Clinical and general laboratory findings.

Authors:  C V Sumaya; Y Ench
Journal:  Pediatrics       Date:  1985-06       Impact factor: 7.124

6.  Epstein-Barr virus infectious mononucleosis in children. II. Heterophil antibody and viral-specific responses.

Authors:  C V Sumaya; Y Ench
Journal:  Pediatrics       Date:  1985-06       Impact factor: 7.124

7.  Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis.

Authors:  R J Risdall; R W McKenna; M E Nesbit; W Krivit; H H Balfour; R L Simmons; R D Brunning
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

8.  Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.

Authors:  S A Riddler; M C Breinig; J L McKnight
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

9.  Transformation and chromosome changes induced by Epstein-Barr virus in normal human leukocyte cultures.

Authors:  P Gerper; J Whang-Peng; J H Monroe
Journal:  Proc Natl Acad Sci U S A       Date:  1969-07       Impact factor: 11.205

10.  Leukocyte response in childhood infectious mononucleosis. Caused by Epstein-Barr virus.

Authors:  G R Fleisher; J E Paradise; E T Lennette
Journal:  Am J Dis Child       Date:  1981-08
View more
  17 in total

1.  Development of a real-time quantitative assay for detection of Epstein-Barr virus.

Authors:  H G Niesters; J van Esser; E Fries; K C Wolthers; J Cornelissen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Quantitative molecular virology in patient management.

Authors:  W Preiser; B Elzinger; N S Brink
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 3.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

4.  Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system.

Authors:  J Loeffler; N Henke; H Hebart; D Schmidt; L Hagmeyer; U Schumacher; H Einsele
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Chronic herpesvirus reactivation occurs in aging.

Authors:  Raymond P Stowe; Elena V Kozlova; Deborah L Yetman; Dennis M Walling; James S Goodwin; Ronald Glaser
Journal:  Exp Gerontol       Date:  2007-01-30       Impact factor: 4.032

Review 6.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

7.  Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.

Authors:  S J Stevens; I Pronk; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

8.  Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood.

Authors:  H Hakim; C Gibson; J Pan; K Srivastava; Z Gu; M J Bankowski; R T Hayden
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

9.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Study of mother-to-child Epstein-Barr virus transmission by means of nested PCRs.

Authors:  M C Meyohas; V Maréchal; N Desire; J Bouillie; J Frottier; J C Nicolas
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.